Asymchem, a contract development and manufacturing organisation (CDMO), has introduced an innovative artificial intelligence (AI) platform to transform protein design. Known as STAR (Sequence Recommendation via Artificial Intelligence), this platform aims to tackle the time-consuming challenges associated with protein engineering.
Avid Bioservices, Inc., a contract development and manufacturing organization (CDMO), announced a definitive merger agreement to be acquired by GHO Capital Partners and Ampersand Capital Partners in an all-cash transaction valued at approximately $1.1 billion. As part of the merger
Huons, a Korean healthcare company, announced today its acquisition of a 31.5% stake in PanGen Biotech, representing a strategic 14.3 billion won investment. This move will establish Huons as the largest shareholder in PanGen, enabling it to expand into the
Vitrian, a provider of investment capital and capacity-building services for biomanufacturing, has announced a $50 million investment in AmplifyBio’s Manufacturing Enablement Center (AMEC) in New Albany, Ohio. This funding, which could extend to $65 million, represents the first phase of
NJ Bio and Charles River Laboratories have entered a strategic alliance to enhance and streamline the development and manufacturing of antibody drug conjugates (ADCs) for their clients. The partnership will integrate both companies’ complementary capabilities, covering early development, optimisation, and
Evotec SE has announced the sale of its chemical API-focused CDMO facility, Evotec DS GmbH, located in Halle/Westphalia, Germany, to private equity firm Monacum Partners. The divestment is part of Evotec’s “Priority Reset” initiative, launched in April 2024, designed to
Concept Life Sciences (CLS), a UK-based organisation specialising in drug discovery, development, and manufacturing, has announced the acquisition of Loughborough-based Charnwood Discovery. Supported by Limerston Capital, this acquisition aims to reinforce CLS’s position in the global pharmaceutical and life sciences
FUJIFILM Diosynth Biotechnologies has completed the initial phase of its production capacity expansion at its Hillerød, Denmark site. This expansion adds six 20,000 L mammalian cell bioreactors, doubling the site’s capacity and bringing its total to 12 bioreactors, in a
LOG Pharma Primary Packaging, a provider of packaging solutions for the pharmaceutical industry, has officially opened a new clean room designed to meet the stringent requirements of pharmaceutical manufacturing. The facility is part of a broader 600-square meter expansion of
FUJIFILM Diosynth Biotechnologies has entered a multi-year agreement with TG Therapeutics to manufacture BRIUMVI (ublitiximab-xiiy), a U.S. FDA-approved treatment for relapsing multiple sclerosis (RMS). As part of the agreement, FUJIFILM Diosynth will provide secondary manufacturing from its upcoming biopharmaceutical facility
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
